<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl3" position="float"><object-id pub-id-type="doi">10.7554/eLife.18082.008</object-id><label>Table 3.</label><caption><p>Antibiogram of <italic>Enterococcus</italic> spp. causing bacteraemia in Northeast Thailand.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.008">http://dx.doi.org/10.7554/eLife.18082.008</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Antibiotic category</th><th valign="top">Antibiotic agents</th><th valign="top">CAB <break/>(n&#160;=&#160;176 patients)</th><th valign="top">HCAB <break/>(n&#160;=&#160;49 patients)</th><th valign="top">HAB <break/>(n&#160;=&#160;117 patients)</th><th valign="top">p values</th></tr></thead><tbody><tr><td valign="top">Aminoglycosides</td><td valign="top">Gentamicin <break/>(high level)</td><td valign="top">35/153 (23%)</td><td valign="top">24/45 (53%)</td><td valign="top">63/101 (62%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Streptomycin</td><td valign="top">Streptomycin <break/>(high level)</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td rowspan="3" valign="top">Carbapenems*</td><td valign="top">Imipenem</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Meropenem</td><td valign="top">1/1 (100%)</td><td valign="top">NA</td><td valign="top">3/5 (60%)</td><td valign="top">&gt;0.99</td></tr><tr><td valign="top">Doripenem</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td rowspan="3" valign="top">Fluoroquinolones</td><td valign="top">Ciprofloxacin</td><td valign="top">37/44 (84%)</td><td valign="top">9/10 (90%)</td><td valign="top">31/37 (84%)</td><td valign="top">&gt;0.99</td></tr><tr><td valign="top">Levofloxacin</td><td valign="top">5/18 (28%)</td><td valign="top">1/6 (17%)</td><td valign="top">11/15 (73%)</td><td valign="top">0.01</td></tr><tr><td valign="top">Moxifloxacin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td rowspan="2" valign="top">Glycopeptides</td><td valign="top">Vancomycin</td><td valign="top">9/176 (5%)</td><td valign="top">0/49 (0%)</td><td valign="top">6/113 (5%)</td><td valign="top">0.27</td></tr><tr><td valign="top">Teicoplanin</td><td valign="top">0/11 (0%)</td><td valign="top">0/4 (0%)</td><td valign="top">0/10 (0%)</td><td valign="top">-</td></tr><tr><td valign="top">Glycylcyclines</td><td valign="top">Tigecycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Lipopeptides</td><td valign="top">Daptomycin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Oxazolidinones</td><td valign="top">Linezolid</td><td valign="top">0/8 (0%)</td><td valign="top">0/2 (0%)</td><td valign="top">0/4 (0%)</td><td valign="top">-</td></tr><tr><td valign="top">Penicillins</td><td valign="top">Ampicillin</td><td valign="top">20/134 (15%)</td><td valign="top">6/37 (16%)</td><td valign="top">34/81 (42%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Streptogramins*</td><td valign="top">Quinupristin-dalfopristin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td rowspan="2" valign="top">Tetracycline</td><td valign="top">Doxycycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Minocycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">MDR</td><td valign="top"/><td valign="top">0/176 (0%)</td><td valign="top">0/49 (0%)</td><td valign="top">4/117 (3%)</td><td valign="top">0.02</td></tr></tbody></table><table-wrap-foot><fn id="tblfn5"><p>NOTE: Data are number of isolates demonstrating non-susceptible to the antimicrobial over the total number of isolates tested (%). CAB&#160;=&#160;Community-acquired bacteraemia, HCAB&#160;=&#160;Healthcare-associated bacteraemia, HAB&#160;= Hospital-acquired bacteraemia, and NA&#160;=&#160;Not available. The first isolate of each patient was used. MDR: non-susceptible to &#8805;1 agent in &#8805;3 antimicrobial categories.</p></fn><fn id="tblfn6"><p>*Intrinsic resistance in <italic>E. faecium</italic> against carbapenems and in <italic>E. faecalis</italic> against streptogramins. When a species has intrinsic resistance to an antimicrobial category, that category is removed prior to applying the criteria for the MDR definition and is not counted when calculating the number of categories to which the bacterial isolate is non-susceptible.</p></fn></table-wrap-foot></table-wrap>